Biohaven Ltd. $BHVN Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company raised its stake in Biohaven Ltd. (NYSE:BHVN) by 52.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 202,975 shares of the company’s stock after buying an additional 69,894 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Biohaven were worth $1,717,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BHVN. AQR Capital Management LLC increased its stake in Biohaven by 49.4% in the 1st quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock valued at $2,761,000 after purchasing an additional 37,981 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Biohaven by 32.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock worth $1,747,000 after purchasing an additional 17,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Biohaven by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock valued at $14,174,000 after purchasing an additional 41,040 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Biohaven by 80.3% in the first quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock valued at $1,481,000 after buying an additional 27,433 shares in the last quarter. Finally, Quantbot Technologies LP boosted its position in shares of Biohaven by 1,097.8% in the 2nd quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock worth $125,000 after buying an additional 8,102 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Price Performance

BHVN stock opened at $14.67 on Monday. The company has a debt-to-equity ratio of 1.87, a quick ratio of 7.41 and a current ratio of 7.41. Biohaven Ltd. has a 1 year low of $7.48 and a 1 year high of $18.57. The firm has a market cap of $2.21 billion, a P/E ratio of -2.59 and a beta of 1.26. The stock has a 50-day simple moving average of $13.95 and a 200-day simple moving average of $11.63.

Analyst Ratings Changes

A number of equities research analysts recently commented on BHVN shares. Bank of America reissued an “underperform” rating and issued a $11.00 price objective (down from $12.00) on shares of Biohaven in a research note on Monday, June 29th. Raymond James Financial reiterated a “strong-buy” rating on shares of Biohaven in a research report on Wednesday, May 27th. HC Wainwright reissued a “neutral” rating and set a $10.00 price objective on shares of Biohaven in a research note on Tuesday, May 26th. Morgan Stanley cut their price objective on Biohaven from $21.00 to $18.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Biohaven in a research note on Friday, June 26th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $21.62.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.